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The Imaging Task Forceappointedby the EuropeanSocietyof Cardiology (ESC)and the European Association ofCardiovascular Imaging (EACVI)
identified the need to develop appropriateness criteria for the use of cardiovascular imaging in heart failure as a result of continuously increasing
demand for imaging in diagnosis, definition of aetiology, follow-up, and treatment planning. This article presents the report of literature review
performed in order to inform the process of definition of clinical indications and to aid the decisions of the appropriateness criteria voting panel.
The report is structured according to identified common heart failure clinical scenarios.
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Introduction
In the ‘European Society of Cardiology (ESC) Guidelines for the diag-
nosis and treatment of acute and chronic heart failure (HF)’,1 HF is
defined as a syndrome consisting of symptoms and signs resulting
from an abnormality of cardiac structure and/or function. The symp-
toms are non-specific and the signs can be absent in patients receiving
diuretics, so the demonstration of existence of an abnormality of
cardiac structure and/or function is essential for HF diagnosis. Provid-
ing information on cardiac structure and function, imaging has an
important role not only in HF diagnosis, but also in definition of HF
aetiology, in follow-up, and in treatment planning.
Echocardiography represents the first-line cardiovascular imaging
(CVI) modality for the assessment of patients with HF. Cardiac
magnetic resonance (CMR), single photon emission computed tom-
ography (SPECT), positron emission tomography (PET), and cardiac
computed tomography (CCT) complement echocardiography or
represent an alternative to it in the case of suboptimal acoustic
window.
The demand for CVI in HF is constantly increasing as a result of
continuously evolving technology, diversification of indications, and
rise in HF prevalence, partially due to better life expectancy and
higher HF prevalence in the elderly.2,3 The increasing demand neces-
sitates appropriateness criteria for CVI use in HF to assist decision-
making.
A literature review was performed in order to inform the process
of definition of clinical indications for CVI use in the most common
HF clinical scenarios. The present report is structured according to
these clinical scenarios.
HF clinical scenarios
The clinical scenarios belong to the following three categories.
Diagnosis
First diagnosis of HF
Echocardiography is recommended as the CVI modality of choice for
first assessment in suspected HF because of its wide availability,
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bed-side portability, accuracy, safety, and low cost together with its
large evidence base in all clinical scenarios4– 13 and main disadvantage
only is the need for an acoustic window.1 Echocardiography at rest,
using 2D, 3D, contrast, spectral, and colour flow Doppler and
Doppler Myocardial Imaging (DMI) provides information both
regarding cardiac structure (wall dimensions, cavity volumes, and
geometry, structural abnormalities of valves, pericardial thickness,
or effusion) and function (global and regional function of the left
and right ventricle, diastolic function, valvular function, and haemo-
dynamics).4 –18 The increasing prevalence of HF with preserved left
ventricular ejection fraction (LVEF)19 enhances the importance of
echocardiography in HF diagnosis, as the main diastolic dysfunction
assessment and grading modality. About 50% of patients diagnosed
with HF have normal LVEF.19 Echocardiography can assess all diastol-
ic function related parameters20 while CMR can also assess some of
them.1 Although not often, radionuclide angiography can be used for
systolic and diastolic function assessment.21 Furthermore, systolic
and diastolic function can be assessed by gated SPECT22 at the
time of myocardial perfusion assessment.
The initial HF diagnosis can be complemented by other imaging
modalities, particularly by CMR,1,23– 28 which provides gold standard
assessment of LV/RV volumes, EF, and cardiac mass, as well as provid-
ing non-invasive in vivo myocardial tissue characterization; arrhyth-
mias can limit the precision of CMR LV volumes/EF assessment and
other disadvantages of CMR are represented by claustrophobia,
overt renal failure (relative contraindications), and the presence of
magnetic resonance imaging (MRI)-conditional devices, and cerebral
metallic clips (absolute contraindications).1
Transoesophageal echocardiography (TOE) can be used for LV as-
sessment in the case of poor transthoracic window, if CMR is not
available or not applicable (ventilated patient or contraindications).
TOE assessment of valves (particularly mitral or prosthetic valves)
can add important information, being essential in suspected endocar-
ditis induced valvular abnormality resulting in HF. Also, left atrial
appendage thrombusexclusionbyTOEmaybeneeded inHFpatients
with atrial fibrillation prior to cardioversion.
Symptomatic patient
Echocardiography is recommended as the first CVI modality of
choice in patients with symptoms suggestive of HF.
In symptomatic patients with emergency presentation, echocardi-
ography is recommended immediately in the case of haemodynamic
compromise and early during hospitalization in the other cases. TOE
may be necessary in suspected endocarditis or if the transthoracic
window is poor, particularly in mechanically ventilated patients.
In symptomatic patients with elective presentation, in the absence
of cardiac history, echocardiography is recommended in the case of
elevated natriuretic peptide.
Asymptomatic (screening)
Screening first-degree relatives of cardiomyopathy patients, we can
identify individuals with cardiomyopathy and subclinical or clinical
HF. Echocardiography is usually the only imaging modality used for
screening.29,30 CMR may be necessary, for example, to exclude or
confirm arrhythmogenic right ventricular cardiomyopathy or to
identify infiltration. Serial testing is necessary in the absence of
genetic exclusion of disease or in genotype-positive but phenotype-
negative individuals. The screening timing and follow-up intervals
have been described by the ESC Working Group on Myocardial
and Pericardial Diseases.29,30
Patients on cardiotoxic chemotherapy often undergo periodic LV
systolic function screening, despite lack of HF symptoms or signs. The
same CVI modality should be used at follow-up to ensure compar-
ability. A baseline echocardiogram is performed before commencing
treatment to assess LV systolic and diastolic function, the valves and
unexpected abnormalities. Echocardiography, with standardized
image acquisition and analysis, provides reliable, reproducible, and
cost-effective follow-up of systolic function in the majority of
patients. Endocardial border delineation can be improved with con-
trast administration when needed. 3D echocardiography improves
accuracy and DMI and speckle tracking increase sensitivity for sub-
clinical cardiotoxicity detection.31 Radionuclide LV angiography
with multi-gated acquisition (MUGA) provides accurate and repro-
ducible LV function assessment at the cost of ionizing radiation ex-
posure.32 CMR provides a radiation-free alternative but the high
cost makes it difficult to justify CMR follow-up for patients on cardi-
otoxic drugs, considering the current low incidence of LV systolic
dysfunction as a result of practice changes in oncology.33 Following
gadolinium-contrast administration though, CMR can identify myo-
cardial fibrosis in cancer survivors.34
The high incidence of HF in patients with diabetes justifies screen-
ing for asymptomatic LV systolic dysfunction in this population1 with
or without BNP screening first, particularly in the case of associated
risk factors for CAD, advanced age, hypertension, proteinuria, and
retinopathy.35 Echocardiography is again the CVI modality of
choice for screening, but an alternative modality can be used in the
case of poor acoustic window or need for additional information.
Asymptomatic patients in whom a murmur has been detected or
with ECG abnormalities suggesting a primary or secondary
underlying cardiomyopathy that could lead to HF should also be
investigated.
Patient with cardiac history
(i) History of myocardial infarction.
(ii) History of structural heart disease.
Echocardiography is recommended in patients with a cardiac history
of myocardial infarction or structural heart disease without prior
natriuretic peptide check in the case of elective presentation with
symptoms suggestive of HF.
Diagnosis of HF aetiology
Diagnosis of aetiology begins with echocardiography, which may
suffice for this purpose (echocardiography at rest with or without
stress echocardiography). Other CVI modalities may complement
echocardiography, depending on their availability, affordability, diag-
nostic profile, contraindications, and associated risk.1
Diagnosis of ischaemic aetiology
Echocardiography may suffice for HF ischaemic aetiology diagnosis
in the case of existence of regional wall motion abnormalities with
thinned and highlyechogenic (old, calcified) scarof myocardial infarc-
tion. Systolic dyssynchrony may mislead, giving false appearance of
regional wall motion abnormality. Furthermore, a severely dilated
LV with severely reduced global LV systolic function may have
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apparent regional distribution of systolic dysfunction due to more
pronounced hypokinesia without or with thinning in some areas.
In symptomatic patients with emergency presentation, initial exist-
ence of systolic dysfunction, usually with coronary artery territory
distribution, with subsequent normalization, suggests ischaemic HF
aetiology. This transient systolic dysfunction is due to myocardial
stunning following an episode of acute ischaemia,36 phenomenon
which can persist for a few hours. Myocardial stunning may occur
in both symptomatic and silent ischaemia and it can provoke ischae-
mic mitral regurgitation of similar transient nature. When performed
late, echocardiography may miss these transient abnormalities.
Strain assessment with echocardiography may detect ischaemia
induced abnormal regional myocardial deformation in HF due to a
non-ST-elevation acute coronary syndrome.37
Echocardiography at rest can be complemented by stress echocar-
diography, CMR and perfusion CMR, SPECT, CT coronary angiog-
raphy or PET.
Stress echocardiography can be used to reveal inducible ischaemia
as reason for an episode of unexplained acute pulmonary oedema. It
can be also used detect viability,13 by demonstrating existence of ino-
tropic reserve with an increase in regional (in a coronary artery ter-
ritory) and global LV systolic function. A low dose dobutamine
infusion protocol with prolonged (5 min) stages is used for this
purpose. Inotropic reserve is recruited in the case the systolic dys-
function is due to myocardial hibernation,38– 41 a phenomenon due
to chronic post-ischaemic dysfunction resulting from cumulative
stunning.36 Inotropic reserve is also recruited in the case the systolic
dysfunction is due to non-transmural infarct. Continuous improve-
ment in systolic function throughout the test is observed in the
case of non-ischaemic aetiology of systolic dysfunction. A bi-phasic
responsecan beobserved in the caseof existenceofflow limiting cor-
onary disease, with drop in regional systolic function after an initial
increase. Only in the case of bi-phasic response demonstration
does stress echocardiography add information regarding ischaemic
aetiology to the information provided by rest echocardiography.
Depending on availability and local expertise, CMR can be used for
coronary artery disease (CAD) diagnosis in HF patients and for via-
bility assessment.40– 44 Since regional wall motion abnormalities
can also be found in non-ischaemic cardiomyopathies, the specificity
of cine-imaging alone for CAD detection is limited.45 Late gadolinium
enhancement (LGE) assessment post contrast injection may help the
differential diagnosis based on the distinct distribution patterns of
contrast in ischaemic and non-ischaemic cardiomyopathies.46 Suben-
docardial or transmural LGE is present in most ischaemic HF patients
(sensitivity 86%).47 CMR has good performance in CAD diagno-
sis.48,49 It can predict reversibility of wall thinning due to myocardial
hibernation rather than necrosis.42 LGE CMR predicts systolic
function recovery following revascularisation.50,51 T1 mapping is a
recently developed CMR technique, which allows the detection of
interstitial myocardial fibrosis, an early marker of disease that has
an evolving role in HF.52 CMR can be used for detection of inducible
ischaemia, either by detecting inducible regional wall motion abnor-
malities or by assessing myocardial perfusion. Inducible regional wall
motion abnormalities assessed with dobutamine stress CMR, similarly
to dobutamine stress echocardiography, carries an increased risk in HF
patients with severely reduced LV systolic function and high likelihood
of proximal coronary disease. Myocardial perfusion assessment is
performed with vasodilator stress (usually adenosine)53 so it is safe
for use even in suspected acute coronary syndromes.54
SPECT can be used to detect ischaemia and viability, providing
diagnostic and prognostic information.1,55– 58 Thallium-201 (201Tl)
and technetium-99m (99mTc) labelled tracers (sestamibi and tetro-
fosmin) are commonly used. Exposure to ionizing radiation, relatively
low spatial resolution and attenuation artefacts are disadvantages of
SPECT.36 Nevertheless, there is extensive evidence that SPECT can
predict global and regional systolic function improvement after revas-
cularisation.36 The CAD diagnosis relies on existence of flow hetero-
geneity and as such, SPECT should be used with caution for diagnosis
of HF aetiology because of the likelihood of falsely negative results in
balanced ischaemia with uniform radioisotope uptake encountered
in 5–10% of patients with three vessels coronary disease.59
PET or PET–CT can be used for assessment of both ischaemia and
viability.1 PET has superior spatial resolution compared with SPECT.
Ischaemia can be evaluated using perfusion tracers like Rubidium-82,
Nitrogen-13 ammonia, or Oxygen-15 water. For viability detection,
F-18-fluorodeoxyglucose (FDG) is most commonly used. Among
viability imaging modalities, FDG PET has the highest sensitivity and
is regarded as the gold standard.60,61 PET can predict improvement
in HF symptoms, functional status, quality of life62,63 global, and re-
gional systolic function post revascularisation.36 Limitations are the
need for a cyclotron on site36 when very short half-life radiotracers
are used, the high cost and the exposure to radiation.1
CT calcium scoring and CT coronary angiography can be used in
HF patients1,64 mainly for CAD diagnosis, having the advantage of
their non-invasive nature. The absence of coronary calcium on CT
virtually excludes CAD as cause the of HF. CT coronary angiography
can reliably rule out CAD, being most effective in patients with a rela-
tive low probability of ischaemic HF aetiology.65,66 Disadvantages are
the exposure to radiation and the potential contrast nephrotoxicity
of CT coronary angiography often relevant in patients with renal im-
pairment at the time of HF diagnosis. Limited data and current prac-
tical challenges prevent recommendation of late-enhancement CT
for viability detection.67
Diagnosis of non-ischaemic aetiology
Echocardiography is the first test of choice and often sufficient for
non-ischaemic HF aetiology diagnosis (valve disease, cardiac
tumours, pericardial disease, congenital heart disease, non-ischaemic
LV systolic dysfunction, or LV diastolic dysfunction).
Valve disease can be identified on the initial echocardiogram per-
formed to investigate HF symptoms and signs. The degree of valvular
abnormality may be enough to explain HF (e.g. severe mitral regurgita-
tion or moderate mixed aortic and mitral valve disease). Further as-
sessment with stress echocardiography is needed if the degree of
valvular abnormality at rest does not justify HF. Stress echocardiog-
raphy with supine bicycle exercise is needed in moderate mitral regur-
gitation to detect a dynamic component (increase in regurgitation
severity on exertion). Changes in pulmonary artery pressure during
exercise have prognostic and therapeutic importance. For assessment
of mitral stenosis, both supine bicycle exercise and dobutamine stress
echo can be appropriate.Withexercise, increase in mean transvalvular
gradient to.15 mmHgand increase insystolicpulmonaryarterypres-
sure (SPAP) to.60 mmHgsuggest severemitral stenosis.With dobu-
tamine, increase in mean gradient to .18 mmHg suggests severe
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mitral stenosis; SPAP changes are not interpretable. In the case of sus-
pectedsevereparadoxical lowflowaortic stenosis, bothsupinebicycle
exercise echo and low dose dobutamine stress echo can be appropri-
ate. In low flow low gradient aortic stenosis with reduced LV EF, low
dose dobutamine stress echo is the classical investigation of choice,
for assessment of both flow reserve and valve compliance to flow.
Nevertheless, usually patients can exercise enough to trigger sufficient
myocardial recruitment and flow increase at low workload for severity
ofdiseasediagnosis.Whenexistenceofflowreserveandsignificant ex-
ertion induced rise in transvalvular gradient with or without concomi-
tant increase in functional valve area are demonstrated, supine bicycle
exercise echocardiography can be diagnostic. In the case of a negative
result for existence of flow reserve or in the case of suboptimal exer-
cise, low dose dobutamine stress echo should be performed. CMR is
the second line imaging modality in valve disease, and sometimes it
can complement echocardiography.68–71 CMR provides information
regarding the surrounding anatomy (great vessels), accurate quantifi-
cation of ventricular volumes and regurgitations, as well as assessment
of myocardial fibrosis, which carries prognostic information.72
Diagnosis of cardiac tumours or of cardiac involvement by tumour
as reason for HF can be made by echocardiography. CMR may
complement the echocardiography diagnosis.1
The diagnosis of pericardial disease as reason for HF can be made
by echocardiography. Cardiac CT or CMR can complement the
diagnosis.1
Even if echocardiography can provide afirst diagnosis of congenital
heart disease and can usually suffice for a complete comprehensive
evaluation, CMR is the CVI modality of choice in complex congenital
heart disease.1,73
Non-ischaemicLVsystolic dysfunction is diagnosedbyexclusion of
CAD, described in the ‘Diagnosis of ischaemic aetiology’ section.
Diastolic dysfunction is diagnosed as reason for HF in the absence
of LV systolic dysfunction, valvular abnormality or pulmonary hyper-
tension which to explain the HF symptoms and signs. Diastolic dys-
function is usually diagnosed by echocardiography. Morphologic
correlates of diastolic dysfunction (LV hypertrophy and left atrial dila-
tation17) can be diagnosed by echocardiography or CMR. Serial
studies of morphologic correlates (cardiac mass, left atrial volume)
for follow-up of disease progression or regression can be performed
more accurately with CMR.14 Furthermore, CMR provides tissue
characterization, detecting infiltration, or inflammation.14 Functional
correlates of diastolic dysfunction—left atrial function and pulmon-
ary artery systolic and diastolic pressure17—can be diagnosed by
echocardiography or invasive cardiac catheterization. LV relaxation,
filling, diastolic distensibility, and diastolic stiffness are assessed with
cardiac catheterisation.14 Echocardiography can provide a compre-
hensive complete diastolic function study. In the case of inconclusive
diastolic parameters at rest and no other diagnostic structural cardiac
abnormality, exercise echocardiography, ideally with a supinebicycle,
can be used for diagnosis.17 CMR can provide many filling parameters
similar to echocardiography14 but it is not used routinely due to the
need for specific image acquisition and lengthy analysis. Radionuclide
angiography can assess all parameters of diastolic function, but its use
is limited nowadays.21 Diastolic function can also be assessed by myo-
cardial perfusion gated SPECT.22
Cardiomyopathies can be first diagnosed as a result of presenta-
tion with HF symptoms and signs. Usually, echocardiography alone
makes the diagnosis.30 CMR may be needed, for example to diagnose
arrhythmogenic right ventricular cardiomyopathy or to confirm an
echocardiographic diagnosis by identifying inflammation or infiltra-
tion with tissue characterisation.74,75 Myocardial inflammation and
oedema are diagnosed with T2 weighted CMR imaging, whereas myo-
cardial infiltration and fibrosis are diagnosed with T1 weighted CMR
imaging post contrast (LGE). Non-ischaemic LGE patterns include
mid-wall, epicardial, and patchy. For example, mid-wall LGE can be
detected in dilated cardiomyopathy (DCM)75 albeit it cannot indicate
the underlying aetiology (idiopathic DCM vs. DCM secondary to
myocarditis).47 Amyloidosis can have a characteristic diffuse LGE,
or a zebra pattern LGE coupled with a typical dark myocardial
cavity due to very abnormal contrast kinetics.76
Treatment planning
Imaging plays a central role in HF treatment planning, being used for
risk stratification and to predict treatment benefit.
Revascularization
Coronary revascularization may improve LV systolic function in
ischaemic HF, by reversing systolic dysfunction due to hibernation
rather than infarction. The benefit depends not only on the existence
of regional viability, but also on the existence of appropriate revascu-
larization targets in the respective coronary arteries and on the
degree of LV remodelling.
HF and angina symptoms
Based on evidence, revascularization is recommended in patients
with angina and HF due to ischaemic LV systolic dysfunction.77 In
the case of severe proximal CAD, the ESC recommends surgical
revascularization regardless of anyotherconsiderations.77 Concomi-
tant surgical ventricular reconstruction may be necessary when the
LV end-systolic volume index is .60 mL/m2 and there is transmural
scar in the LAD (left anterior descending artery) territory. Percutan-
eous coronary intervention may replace CABG in the case of suitable
coronary anatomy and existence of viability in the respective terri-
tory of distribution.39,77 Evidently, treatment planning implies
imaging based assessment of end-systolic volume and viability. As
detailed in the ‘Diagnosis of ischaemic aetiology’, echocardiography
can provide this assessment, and so does CMR.40,41 SPECT or PET
can be used to detect viability.41 In the case of angina symptoms,
HF patients will have invasive coronary angiography performed for
CAD diagnosis, making usually unnecessary the detection of indu-
cible ischaemia and consequently reducing the risk of a dobutamine
stress echocardiography viability test.
HF without angina symptoms
In the absence of angina, revascularization planning is strictly based on
existence of viability, increasing further the significance of the above
discussed considerations.77 The Surgical Treatment for Ischaemic
Heart Failure (STICH) Trial78 found lower ratesof death fromcardio-
vascular causes and of hospitalization for cardiovascular causes in HF
patients treated with CABG revascularization. Nevertheless, a sub-
study of the STICH Trial,79 despite finding greater likelihood of sur-
vival in patients with viability, found no differential survival benefit
of revascularization based on diagnosed viability. However, many
criticisms accompanied this sub-study, including the fact that
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viability imaging was offered at the physicians’ discretion, rather than
randomization.
LV aneurysmectomy is recommended at the time of surgical revas-
cularisation77 and in this regard, thedefinitionof the transition zone in
between the scarred and not scarred myocardium is of major signifi-
cance. LGE CMR or transthoracic echocardiography can be per-
formed before the procedure80 while TOE can be performed
intraoperatively. Echocardiography has the advantage of concomi-
tantly assessing the mitral valve for need of repair, based on assess-
ment at rest or during exercise. CMR has the advantage of accurate
assessment of volumes and better definition of the transition
zone and it represents the gold standard for patient selection for
aneurysmectomy.80
Contrast echocardiography, CMR,81 or CCT can all assess the
existence of mural thrombus prior to surgery.
No symptoms
In the absence of symptoms, detection of inducible ischaemia should
complement the above discussed investigations. Considerations dis-
cussed in the ‘Diagnosis of ischaemic aetiology’ are appropriate in this
regard.
Device therapy
Accurate assessment of LV EF is essential for deciding on device
therapy.82 Echocardiography is the first CVI modality of choice for
LV EF assessment. 2D echocardiography can be used to assess LV
EF with the bi-plane method, with or without the help of contrast
to improve endocardial delineation. 3D echocardiography provides
accurate and reproducible LV EF assessment. CMR provides gold
standard assessment of LV EF and can be used in patients with
poor acoustic window. Gated SPECT can be also used in patients
with poor acoustic window and CMR contraindications.
Implantable cardioverter defibrillator planning
LV EF assessment with or without assessment of existence of
ischaemic aetiology of HF are necessary for implantable cardioverter
defibrillator (ICD) implantation planning. Echocardiography is the
first CVI modality. Accurate LV EF assessment is essential for
decision-making. CMR, MUGA, or gated SPECT can be used for LV
EF assessment in patients with poor acoustic window. Considerations
extensively presented in the ‘Diagnosis of ischaemic aetiology’ are
relevant for aetiology assessment. There is emerging evidence that
LGE CMR can predict ventricular arrhythmic events in ischaemic
cardiomyopathy.83,84
Cardiac resynchronization therapy (CRT) planning
A complete echocardiographic assessment is recommended85
beforeconsideringCRT. As for ICD planning, accurate EFassessment
is essential and can be performed with echocardiography, CMR,
MUGA, or gated SPECT. Viability assessment may be needed in the
case of myocardial infarct involving potential LV lead placement
areas (basal infero-lateral or lateral wall). CMR has been used to
guide LV lead placement avoiding areas of transmural infarct86 and
to predict clinical outcome in CRT patients based on assessment of
the right ventricle.87,88
Cardiac CT can visualize the coronary veins non-invasively if pre-
procedural planning of LV lead placement is needed.
There is a wealth of echocardiography research performed in the
field of dyssynchrony,89– 95 using DMI derived techniques, speckle
tracking, 3D regional volume curves analysis, and even M-mode.
Nevertheless, based on currently existent evidence, echocardio-
graphic dyssynchrony assessment should not be used to exclude
patients from CRT.85 Similarly, gated SPECT phase analysis,96 gated
PET/CT,97 andCMRtechniques53,98 have been studied for the assess-
ment of dyssynchrony. In the absence of relevant randomized control
trials though, no CVI assessment of dyssynchrony should be used for
clinical decision-making.99
LV assist device
A complete echocardiographic assessment is needed before consid-
ering an LV assist device. Accurate assessment of LV EF is essential82




Echocardiography is the first imaging modalityof choice for follow-up
of HF progression or regression on medical treatment or in patients
treated with CRT. CMR can be used for follow-up when acoustic
window is suboptimal and in the absence of an implanted non-MRI-
conditional device (which prohibits the use of CMR).
CRT follow-up
Based oncurrentevidence, echocardiography follow-up85 for assess-
ment of LV volumes and EF together with assessment of functional
mitral regurgitation and pulmonary hypertension is recommended.
Echocardiography based CRT optimization may be useful but it is
not strongly recommended85 based on current evidence.
New symptoms
A complete echocardiogram is necessary in the case new symptoms
develop. Findings may justify involvement of an alternative CVI
modality, mirroring already described scenarios.
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